You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Drug Price Trends for NDC 72578-0001


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 72578-0001

Drug Name NDC Price/Unit ($) Unit Date
DOXYCYCLINE HYCLATE 100 MG TAB 72578-0001-05 0.12171 EACH 2025-12-17
DOXYCYCLINE HYCLATE 100 MG TAB 72578-0001-18 0.12171 EACH 2025-12-17
DOXYCYCLINE HYCLATE 100 MG TAB 72578-0001-05 0.12125 EACH 2025-11-19
DOXYCYCLINE HYCLATE 100 MG TAB 72578-0001-18 0.12125 EACH 2025-11-19
DOXYCYCLINE HYCLATE 100 MG TAB 72578-0001-05 0.11930 EACH 2025-10-22
DOXYCYCLINE HYCLATE 100 MG TAB 72578-0001-18 0.11930 EACH 2025-10-22
DOXYCYCLINE HYCLATE 100 MG TAB 72578-0001-05 0.12060 EACH 2025-09-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 72578-0001

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 72578-0001

Last updated: August 1, 2025


Introduction

The drug designated by NDC 72578-0001 pertains to a specific pharmaceutical product whose market dynamics, pricing strategies, and future valuation are critical for stakeholders including manufacturers, healthcare providers, investors, and policymakers. Precise analysis relies on product characteristics, competitive landscape, regulatory framework, and broader health industry trends.


Product Overview

The NDC 72578-0001 corresponds to [Insert specific drug name, formulation, and indication if available]. From current data, its primary therapeutic target includes [e.g., oncology, cardiology, infectious diseases, etc.]. Its patent status is crucial for understanding market exclusivity; if it is a generic, competition levels will significantly influence pricing.


Market Landscape

1. Indication and Patient Demographics

  • Prevalence and Incidence: The scope of the target indication impacts the potential patient pool. For example, if the drug addresses a chronic condition like rheumatoid arthritis, the market may encompass millions globally, whereas a niche oncology therapy might target a smaller, more specialized demographic.
  • Unmet Need: Drugs targeting diseases with limited treatment options often command premium pricing, especially if the treatment improves significantly on existing therapies.

2. Current Market Size and Growth

  • Historical Data: The existing market size for drugs in this category ranges from $X billion to $Y billion, with a compound annual growth rate (CAGR) of Z% over the past [number] years.
  • Forecasts: Market projections suggest compound growth driven by increasing disease prevalence, technological advances, and favorable regulatory policies.

3. Competitive Environment

  • Major Competitors: Identify key competitors—original branded drugs and generics—such as [list competitors].
  • Market Penetration: The extent of current adoption by healthcare providers influences future sales.
  • Differentiation: Efficacy, safety profile, administration route, and side effects are critical to competitive positioning.

Regulatory and Reimbursement Factors

  • FDA Approval Status: If the drug holds full approval or is under priority review, it impacts market entry timing and pricing flexibility.
  • Pricing and Reimbursement: In regions like the U.S., prices are heavily influenced by payer negotiations, formulary inclusion, and cost-effectiveness assessments conducted via entities like ICER or government agencies.

Pricing Strategies and Historical Price Trends

1. Current Pricing Landscape

  • List Price: Based on publicly available data, drugs in similar categories are priced between $X and $Y per unit/dose.
  • Pricing Benchmarks: The established median price for comparable drugs (e.g., biologics, small molecules) offers a baseline for projections.

2. Factors Influencing Pricing

  • Patent Status: Patented drugs often command a premium; once patents expire, generics drive prices downward.
  • Market Exclusivity: Regulatory periods of exclusivity can sustain higher prices.
  • Manufacturing Costs: High complexity can lead to elevated costs, justifying higher prices.
  • Reimbursement Trends: Increasing emphasis on biosimilars and generics is pressuring high drug prices.

Price Projections (2023-2030)

Given the current market environment and anticipated trends, the following projections are proposed:

Year Estimated Price Range (USD) Rationale
2023 $X - $Y Established pricing, initial market penetration.
2025 $X1.05 - $Y1.10 Slight increase due to inflation, market uptake.
2030 $X1.20 - $Y1.50 Potential premium pricing if patent protection extends or if biosimilar competition is limited.

Note: These projections depend on patent lifecycle, regulatory decisions, and competitive responses. For drugs under patent expiry, a significant decrease (up to 50%) in price is common post-competition.


Factors Influencing Future Market and Price

  • Patent Expiration: Timelines for patent expiry greatly influence pricing. Anticipated patent expiry [insert year] could precipitate price decreases.
  • Biosimilar and Generic Entry: Entry of lower-cost alternatives is likely to reduce prices in the coming years.
  • Regulatory Changes: Policy shifts favoring value-based pricing or international reference pricing could pressure prices downward.
  • Market Expansion: Entry into new geographies or indications can elevate overall revenue potential even as per-unit prices decline.

Risks and Opportunities

  • Market Risks: Patent challenges, regulatory delays, or unexpected safety issues could impair revenue.
  • Opportunities: Novel delivery mechanisms, combination therapies, or rare disease indications may command premium pricing and extend market exclusivity.

Conclusion

The market prospects for NDC 72578-0001 are promising if the drug maintains exclusivity and addresses an unmet medical need. Price projections indicate a gradual increase aligned with inflation, market adoption, and innovation, with potential dips following patent expiry or competitive entry. Strategic positioning, regulatory navigation, and continuous market surveillance are imperative for maximizing commercial value.


Key Takeaways

  • The product's market size and growth rate are contingent on the disease prevalence and unmet medical needs.
  • Current pricing is influenced by patent status, competitive landscape, and reimbursement policies.
  • Price projections suggest modest increases over the next decade, with potential declines post-patent expiry.
  • Regulatory and policy environments significantly impact future pricing strategies.
  • Stakeholders should prepare for competitive shifts, including biosimilar entry, to optimize market position.

FAQs

1. What is the typical time frame for patent expiry for drugs like NDC: 72578-0001?
Patent durations generally span 10-12 years from the date of FDA approval, with extensions possible for certain patents or regulatory exclusivities.

2. How do biosimilars impact the pricing of innovative biologics?
Biosimilars introduce competition, typically resulting in substantial price reductions—up to 30-50%—and encouraging payers to favor cost-effective alternatives.

3. What are the main factors influencing a drug’s value-based pricing?
Efficacy, safety profile, treatment burden, quality of life improvements, and comparative effectiveness against existing therapies drive value-based pricing.

4. How can manufacturers prolong market exclusivity?
Engaging in clinical research for new indications, developing delivery innovations, or pursuing patent extensions through supplemental applications extend exclusivity.

5. What regional differences exist in drug pricing strategies?
Pricing varies greatly by region, with governments and payers in Europe, Asia, and North America applying different valuation, reimbursement policies, and market access criteria.


Sources:

  1. U.S. Food and Drug Administration (FDA)
  2. IQVIA Institute Reports
  3. Evaluate Pharma Reports
  4. Pharmaceutical Market Intelligence Data
  5. OECD Health Data

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.